Literature DB >> 1322072

Limited potential for mosquito transmission of a live, attenuated chikungunya virus vaccine.

M J Turell1, F J Malinoski.   

Abstract

Studies were conducted to determine the potential for transmission of a live, attenuated chikungunya (CHIK) virus vaccine by orally exposed or virus-inoculated mosquitoes. The vaccine (CHIK 181/clone 25) replicated in and was transmitted by female Aedes albopictus and Ae. aegypti after intrathoracic inoculation. Mosquitoes also became infected with the vaccine after ingesting virus from either a blood-soaked cotton pledget or a viremic monkey. However, because of the low viremias produced in inoculated humans, it is unlikely that mosquitoes would become infected by feeding on a person inoculated with the live, attenuated CHIK vaccine. Although the vaccine was transmitted by mosquitoes after intrathoracic inoculation, there was no evidence of reversion to a virulent phenotype.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1322072     DOI: 10.4269/ajtmh.1992.47.98

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  10 in total

1.  Transmission potential of two chimeric Chikungunya vaccine candidates in the urban mosquito vectors, Aedes aegypti and Ae. albopictus.

Authors:  Justin R Darwin; Joan L Kenney; Scott C Weaver
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

2.  Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose.

Authors:  Chad J Roy; A Paige Adams; Eryu Wang; Kenneth Plante; Rodion Gorchakov; Robert L Seymour; Heather Vinet-Oliphant; Scott C Weaver
Journal:  J Infect Dis       Date:  2014-01-07       Impact factor: 5.226

Review 3.  Do we need a vaccine against chikungunya?

Authors:  Giovanni Rezza
Journal:  Pathog Glob Health       Date:  2015-05-14       Impact factor: 2.894

4.  No evidence of chikungunya virus and antibodies shortly before the outbreak on Sri Lanka.

Authors:  Marcus Panning; Dominic Wichmann; Klaus Grywna; Augustina Annan; Sriyal Wijesinghe; S A M Kularatne; Christian Drosten
Journal:  Med Microbiol Immunol       Date:  2009-02-18       Impact factor: 3.402

5.  The role of the mosquito in a dengue human infection model.

Authors:  Christopher N Mores; Rebecca C Christofferson; Silas A Davidson
Journal:  J Infect Dis       Date:  2014-06-15       Impact factor: 5.226

6.  Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism.

Authors:  Kenneth Plante; Eryu Wang; Charalambos D Partidos; James Weger; Rodion Gorchakov; Konstantin Tsetsarkin; Erin M Borland; Ann M Powers; Robert Seymour; Dan T Stinchcomb; Jorge E Osorio; Ilya Frolov; Scott C Weaver
Journal:  PLoS Pathog       Date:  2011-07-28       Impact factor: 6.823

7.  Live-attenuated RNA hybrid vaccine technology provides single-dose protection against Chikungunya virus.

Authors:  Emily A Voigt; Jasmine Fuerte-Stone; Brian Granger; Jacob Archer; Neal Van Hoeven
Journal:  Mol Ther       Date:  2021-05-29       Impact factor: 12.910

Review 8.  Chikungunya Virus: Pathophysiology, Mechanism, and Modeling.

Authors:  Vaishnavi K Ganesan; Bin Duan; St Patrick Reid
Journal:  Viruses       Date:  2017-12-01       Impact factor: 5.048

Review 9.  Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy.

Authors:  Simon-Djamel Thiberville; Nanikaly Moyen; Laurence Dupuis-Maguiraga; Antoine Nougairede; Ernest A Gould; Pierre Roques; Xavier de Lamballerie
Journal:  Antiviral Res       Date:  2013-06-28       Impact factor: 5.970

Review 10.  Macaque models of human infectious disease.

Authors:  Murray B Gardner; Paul A Luciw
Journal:  ILAR J       Date:  2008
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.